Drug intelligence / Profile preview

BNT165d

Development stage: Phase 2
Lead developer: BioNTech
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular

Overview

BNT165d is an investigational mRNA-based vaccine component developed by BioNTech for the prevention of malaria caused by Plasmodium falciparum. It is a constituent of the multi-antigen vaccine candidate BNT165e. BNT165d is a combination of two distinct RNAs, BNT165d1 and BNT165d2, which encode conserved, immunogenic segments of proteins expressed during the liver stage of the P. falciparum life cycle. These RNAs are encapsulated in lipid nanoparticles (LNPs) to facilitate delivery and induce a protective immune response against the parasite before it reaches the symptomatic blood stage.

Beyond the preview

Go deeper on BNT165d.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNT165d.

Explore the full profile